Austrianni

Executive Summary

Austrianni GmbH is a privately held Austrian pharmaceutical company founded in 2018 with a singular focus on developing novel therapeutics for the prevention and treatment of tuberculosis (TB). Based in Vienna, the company leverages expertise in antibodies, biologics, and small molecules to address the global TB epidemic, which remains one of the leading infectious disease killers worldwide. Despite limited publicly available data on its pipeline, funding, or clinical stage, Austrianni's mission aligns with significant unmet medical need and growing public health initiatives to combat drug-resistant TB. The company operates in a niche but critical area, and its early-stage status suggests potential for future milestones as it advances preclinical candidates. However, the absence of disclosed financials, partnerships, or regulatory progress introduces uncertainty regarding near-term value inflection points.

Upcoming Catalysts (preview)

• TBDPreclinical candidate nomination for lead TB therapeutic40% success
• TBDSecuring grant or non-dilutive funding from EU or global health foundations50% success
• TBDEstablishment of research collaboration or licensing deal35% success